Martina Tinelli
Overview
Explore the profile of Martina Tinelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barila G, Quaglia F, Furlan A, Pescosta N, Bonalumi A, Marcon C, et al.
Ann Hematol
. 2023 Sep;
103(1):125-132.
PMID: 37731147
Treatment of lenalidomide refractory (Len-R) multiple myeloma (MM) patients still represents an unmet clinical need. In the last years, daratumumab-bortezomib-dexamethasone (D-VD) combination was extensively used in this setting, even though...
2.
Cosentini V, Vitale M, Gammaro L, Petrolino A, Tinelli M, Remo A, et al.
G Ital Nefrol
. 2020 Aug;
37(4).
PMID: 32809284
Amyloidosis represents a heterogeneous group of pathologies characterized by the deposit, in the form of fibrils, in the various organs and tissues of the body, of abnormal proteins; the deposits...
3.
Bonifacio M, Scaffidi L, Binotto G, Miggiano M, Danini M, Minotto C, et al.
Leuk Res
. 2018 Oct;
74:75-79.
PMID: 30308414
The use of generic drugs after patent expiration of their originators is a relative novelty in the treatment of chronic cancer patients in Western countries. In this observational study we...
4.
Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, et al.
Br J Haematol
. 2018 May;
184(6):1052-1055.
PMID: 29726006
No abstract available.
5.
Guglielmi V, Nowis D, Tinelli M, Malatesta M, Paoli L, Marini M, et al.
J Neuropathol Exp Neurol
. 2017 Sep;
76(7):620-630.
PMID: 28863457
Multiple myeloma (MM) accounts for ∼13% of all hematologic malignancies. Bortezomib treatment is effective in MM, but can be complicated with neurological side effects. We describe a patient with symptomatic...
6.
Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, et al.
Br J Haematol
. 2017 Jun;
178(5):781-793.
PMID: 28597546
New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasma cells (PCs) represent attractive new therapeutic targets. The endothelin-1 (EDN1) axis,...
7.
Mian M, Tinelli M, De March E, Turri G, Meneghini V, Pescosta N, et al.
Anticancer Res
. 2016 Mar;
36(3):1059-65.
PMID: 26976998
Treatment of multiple myeloma (MM) has significantly improved, although the disease remains incurable. Prospective clinical trials evaluating the impact on outcome of new drugs such as proteasome inhibitors or immunomodulating...
8.
Cavallini C, Lovato O, Bertolaso A, Zoratti E, Malpeli G, Mimiola E, et al.
Oncotarget
. 2015 Sep;
6(31):32061-74.
PMID: 26393680
TNF-like ligand 1A (TL1A) and its unique receptor death receptor 3 (DR3) acts as broad T-cell costimulator involved in regulatory mechanisms of adaptive immune response under physiological and pathological settings....
9.
Nichele I, Zamo A, Bertolaso A, Bifari F, Tinelli M, Franchini M, et al.
PLoS One
. 2013 Jan;
7(12):e52811.
PMID: 23285191
Background: small B-cell neoplasms can show plasmacytic differentiation and may potentially progress to aggressive lymphoma (DLBCL). Epstein-Barr virus (EBV) infection may cause the transformation of malignant cells in vitro. Design...
10.
Sartoris S, Mazzocco M, Tinelli M, Martini M, Mosna F, Lisi V, et al.
Stem Cells Dev
. 2010 Aug;
20(4):709-19.
PMID: 20695752
Bone marrow mesenchymal stromal cells (BM-MSCs) may survive and proliferate in the presence of cycling neoplastic cells. Exogenously administered MSCs are actively incorporated in the tumor as stromal fibroblasts, thus...